NCT03872778: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

NCT03872778
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: GRPR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03872778

Comments are closed.

Up ↑